The U.S. Food and Drug Administration has announced the retirement of the MedWatch to Manufacturer Program (MMP) as of 31st July 2020. The program provided participating drug and biologic manufacturers with a means of receiving information from the FDA on serious adverse event reports that are submitted directly to the FDA by voluntary reporters.

Since the introduction of the FDA Adverse Event Reporting System (FAERS) public dashboard in 2017, manufacturers can directly search and download publicly available information from adverse event reports, including those submitted  voluntarily. The dashboard is a highly interactive web-based tool where FAERS data can be accessed in a user friendly fashion and allows manufacturers to obtain information more promptly in comparison to receiving this information via the MMP.

The intention of this tool is to expand the access of FAERS data to the public to search for information related to human adverse events reported to the FDA by the pharmaceutical industry, healthcare providers and consumers. The dashboard does not provide case narratives; these can be obtained by submitting a Freedom of Information Act (FOIA) request along with the applicable FAERS case numbers.

The MMP retirement will not adversely affect the FDA’s postmarketing safety monitoring program.

For more information, please review the FDA update available via: https://www.fda.gov/safety/reporting-serious-problems-fda/medwatch-manufacturer-program

Riddhi Parikh

Consultant
ADAMAS Consulting
Riddhi.Parikh@adamasconsulting.com

The ADAMAS Corporate Brochure 2016

 

Brochure – Please download the ADAMAS brochure describing our QA services and contact details.

×
Regulatory Environment

 

The development of medicines is the most regulated industry in the world, and compliance at each stage of the research and development process, as well as after licensing, is critical to ensuring high quality and safe medicines reach patients in a timely manner.

adamas-quality-assurance-services

 

ADAMAS’s consultants have expertise across the G’X’Ps in pre-clinical, clinical and post-licensing areas. They have worked across many different therapeutic areas and product types including oncology, vaccines, biologics, medical devices and gene therapy. As a company we have developed close partnerships with our clients to support them in their development programmes and post-licensing activities, and to guide them successfully through their worldwide regulatory inspections.

 

×
How to be a Clinical Auditor

So you want to be a Clinical Auditor? An article written by CEO.Dr.

×
Benchmarking Data

 

Please download our benchmarking data sheet, to see how these data compare with your own performance. To discuss a more detailed report, or analysis of a data subset, please get in touch.

×

×
Is your QMS compliant?

Identify whether your QMS is compliant to the upcoming ICH GCP Addendum

×
ICH (E6) R2 Addendum - Step 4

 

Please enter your details to complete the download.

×

×
BECOME THE FIRST TO DISCOVER OUR DATA

Want to become one of the first businesses to access our exclusive data?
Get going and start reducing risk today. Pre register now.

×

×
How to be a Clinical Auditor

So you want to be a Clinical Auditor? An article written by CEO.Dr.


×

×